PCOS Has Been Renamed PMOS: What Women Need to Know

A name that was always misleading has finally been changed.

A condition affecting 1 in 8 women worldwide has officially been given a new name. Polycystic ovary syndrome (PCOS) is now polyendocrine metabolic ovarian syndrome (PMOS), following a 14-year global consultation process involving 56 patient and professional organisations. The name change was published in The Lancet this week and announced at the European Congress of Endocrinology.

Why the old name was a problem

The name "polycystic ovary syndrome" pointed to ovarian cysts as the defining feature of the condition. The problem is that not all women with the condition have cysts on their ovaries, and many women without the condition do. Research has since confirmed there is no increase in abnormal ovarian cysts in those diagnosed, making the old name not just imprecise but actively misleading.

That misleading name had real consequences. Delayed diagnosis, fragmented care and missed opportunities to identify metabolic and cardiovascular risks have all been linked to the way the condition was framed and understood. Many women spent years being told their symptoms did not fit, or were only assessed through the narrow lens of reproductive health.

What PMOS reflects that PCOS did not

The new name, polyendocrine metabolic ovarian syndrome, shifts the focus in two important ways. "Polyendocrine" acknowledges that multiple hormonal systems are involved, not just the ovaries. "Metabolic" recognises that the condition has significant effects on weight, blood sugar regulation, cholesterol and cardiovascular risk. These are not secondary features of the condition. For many women, they are the most clinically significant ones.

PMOS is characterised by hormonal fluctuations with effects across the body, including weight, metabolic health, mental health, skin and the reproductive system. Framing it as a whole-body hormonal condition, rather than an ovarian one, is expected to shift how clinicians assess, diagnose and treat it.

What this means in practice

The transition to PMOS will be gradual. A three-year implementation period is underway, supported by an international education campaign for healthcare professionals, researchers and those affected. The new name will be fully incorporated into international clinical guidelines in 2028.

Women currently diagnosed with PCOS do not need to take any action. Their diagnosis remains valid and their care continues under existing guidelines. The change is one of nomenclature and clinical framing, not a redefinition of who qualifies for the diagnosis.

Why this matters now

Professor Helena Teede of Monash University, who led the name change process, described it as a landmark moment that will drive advances in both clinical practice and research. The process involved more than 22,000 survey responses from patients and professionals and was designed to prioritise scientific accuracy, avoidance of stigma and cultural appropriateness across international contexts.

For the estimated 170 million women living with this condition globally, a name that accurately describes what is actually happening in the body is not a minor administrative update. It is the foundation on which better diagnosis, better treatment and better research are built.

References

Teede HJ, Piltonen T, Dokras A et al. Renaming polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome: international consensus. The Lancet. 2026. doi: 10.1016/S0140-6736(26)00717-8

Endocrine Society. Polyendocrine Metabolic Ovarian Syndrome: new name to improve diagnosis and care of condition affecting 170 million women worldwide. Press release, 12 May 2026. endocrine.org

Editorial Note

This article is for informational purposes only and is not a substitute for professional medical advice. If you have concerns about your health, speak to a qualified healthcare professional.